Journal
MICROORGANISMS
Volume 10, Issue 12, Pages -Publisher
MDPI
DOI: 10.3390/microorganisms10122338
Keywords
human milk oligosaccharide; irritable bowel syndrome; gut microbiota; 2'fucosyllactose; Bifidobacterium
Categories
Funding
- BBSRC
- [BB/T008776/1]
Ask authors/readers for more resources
Irritable Bowel Syndrome is a common gastrointestinal disorder, and human milk oligosaccharides show promise as a potential therapeutic option for improving symptoms by altering the gut microbiota.
Irritable Bowel Syndrome (IBS) is the most common gastrointestinal (GI) disorder in Western populations and therefore a major public health/economic concern. However, despite extensive research, psychological and physiological factors that contribute to the aetiology of IBS remain poorly understood. Consequently, clinical management of IBS is reduced to symptom management through various suboptimal options. Recent evidence has suggested human milk oligosaccharides (HMOs) as a potential therapeutic option for IBS. Here, we review literature concerning the role of HMOs in IBS, including data from intervention and in vitro trials. HMO supplementation shows promising results in altering the gut microbiota and improving IBS symptoms, for instance by stimulating bifidobacteria. Further research in adults is required into HMO mechanisms, to confirm the preliminary results available to date and recommendations of HMO use in IBS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available